INTERVENTION 1:	Intervention	0
Epothilone B: Group A	Intervention	1
epothilone b	CHEBI:31550	0-12
group	CHEBI:24433	14-19
Group A: Patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT). Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.	Intervention	2
group	CHEBI:24433	0-5
progressive	HP:0003676	23-34
brain	UBERON:0000955	76-81
brain	UBERON:0000955	105-110
body weight	CMO:0000012	315-326
INTERVENTION 2:	Intervention	3
Epothilone B: Group B	Intervention	4
epothilone b	CHEBI:31550	0-12
group	CHEBI:24433	14-19
Group B: an exploratory cohort of patients, with either leptomeningeal metastases (LMD) or unirradiated, asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.	Intervention	5
group	CHEBI:24433	0-5
brain	UBERON:0000955	118-123
breast cancer	DOID:1612	140-153
body weight	CMO:0000012	339-350
DISEASE CHARACTERISTICS:	Eligibility	0
disease	DOID:4,OGMS:0000031	0-7
Histologically or cytologically confirmed carcinoma of the breast	Eligibility	1
carcinoma	HP:0030731,DOID:305	42-51
breast	UBERON:0000310	59-65
CNS metastases (i.e., brain parenchymal lesions and/or leptomeningeal disease), meeting 1 of the following criteria:	Eligibility	2
brain	UBERON:0000955	22-27
disease	DOID:4,OGMS:0000031	70-77
Recurrent or progressive CNS metastases after whole brain radiotherapy	Eligibility	3
recurrent	HP:0031796	0-9
progressive	HP:0003676	13-24
brain	UBERON:0000955	52-57
radiotherapy	OAE:0000235	58-70
If only evaluable site of CNS progression has been previously treated with stereotactic radiosurgery, radiation necrosis must be excluded by radiographic (e.g., positron emission tomography scan or magnetic resonance spectroscopy) or histologic assessment	Eligibility	4
site	BFO:0000029	18-22
excluded	HP:0040285	129-137
positron	CHEBI:30225	161-169
tomography	BAO:0002525	179-189
Newly diagnosed, untreated, asymptomatic brain or leptomeningeal metastases	Eligibility	5
brain	UBERON:0000955	41-46
Patient must be neurologically stable, as demonstrated by a stable dose of steroids and anticonvulsants for  1 week prior to obtaining baseline gadolinium-enhanced MRI of the brain and/or  1 week prior to beginning study treatment	Eligibility	6
patient	HADO:0000008,OAE:0001817	0-7
stable	HP:0031915	31-37
stable	HP:0031915	60-66
week	UO:0000034	111-115
week	UO:0000034	191-195
brain	UBERON:0000955	175-180
No CNS complications requiring urgent neurosurgical intervention (e.g., resection or shunt placement)	Eligibility	7
Hormone receptor status not specified	Eligibility	8
hormone	CHEBI:24621	0-7
receptor	BAO:0000281	8-16
PATIENT CHARACTERISTICS:	Eligibility	9
patient	HADO:0000008,OAE:0001817	0-7
Male or female	Eligibility	10
male	CHEBI:30780,PATO:0000384	0-4
male	CHEBI:30780,PATO:0000384	10-14
female	PATO:0000383	8-14
Menopausal status not specified	Eligibility	11
Karnofsky performance status 60-100%	Eligibility	12
Life expectancy  3 months	Eligibility	13
Absolute neutrophil count > 1,500/mm^3	Eligibility	14
Hemoglobin > 9.0 g/dL	Eligibility	15
hemoglobin	CHEBI:35143	0-10
Platelet count > 100,000/mm^3 (red blood cell transfusion and repeat evaluation allowed)	Eligibility	16
platelet count	CMO:0000029	0-14
blood	UBERON:0000178	35-40
Bilirubin < 1.5 times upper limit of normal (ULN)	Eligibility	17
AST and ALT < 2.5 times ULN	Eligibility	18
Alkaline phosphatase < 2.5 times ULN	Eligibility	19
phosphatase	GO:0016791,BAO:0000295	9-20
Creatinine < 1.5 times ULN	Eligibility	20
creatinine	CHEBI:16737	0-10
Not pregnant or nursing	Eligibility	21
Negative pregnancy test	Eligibility	22
Fertile patients must use effective contraception during and for 3 months after completion of study therapy	Eligibility	23
No known hypersensitivity to epothilones	Eligibility	24
hypersensitivity	GO:0002524,DOID:1205	9-25
No peripheral neuropathy > grade 1	Eligibility	25
peripheral neuropathy	HP:0009830,DOID:870	3-24
No unresolved diarrhea within the past 7 days	Eligibility	26
diarrhea	HP:0002014,DOID:13250	14-22
Grade 0 diarrhea required at study entry	Eligibility	27
diarrhea	HP:0002014,DOID:13250	8-16
No concurrent serious medical illness (e.g., HIV positivity or active hepatitis B or C)	Eligibility	28
active	PATO:0002354	63-69
hepatitis b	DOID:2043	70-81
No severe cardiac insufficiency (e.g., New York Heart Association class III-IV heart disease) with uncontrolled and/or unstable cardiac or coronary artery disease	Eligibility	29
severe	HP:0012828	3-9
heart	UBERON:0000948	48-53
heart	UBERON:0000948	79-84
heart disease	DOID:114	79-92
coronary artery disease	DOID:3393	139-162
No active or suspected acute or chronic uncontrolled infection, including abscess or fistulae	Eligibility	30
active	PATO:0002354	3-9
acute	HP:0011009,PATO:0000389	23-28
chronic	HP:0011010	32-39
abscess	HP:0025615	74-81
No other malignancy within the past 3 years except curatively treated nonmelanoma skin cancer, prostate cancer, or carcinoma in situ of the cervix	Eligibility	31
skin cancer	DOID:4159	82-93
prostate cancer	HP:0012125,DOID:10283	95-110
carcinoma	HP:0030731,DOID:305	115-124
No history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits	Eligibility	32
history	BFO:0000182	3-10
No contraindications to MRI, including any of the following:	Eligibility	33
Pacemaker	Eligibility	34
Ferromagnetic implants	Eligibility	35
Claustrophobia	Eligibility	36
claustrophobia	HP:0025253	0-14
Extreme obesity	Eligibility	37
obesity	HP:0001513,DOID:9970	8-15
PRIOR CONCURRENT THERAPY:	Eligibility	38
See Disease Characteristics	Eligibility	39
disease	DOID:4,OGMS:0000031	4-11
More than 2 weeks since prior noncytotoxic drugs (e.g., small molecule-targeted drugs) and recovered	Eligibility	40
More than 3 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered	Eligibility	41
mitomycin c	CHEBI:27504	82-93
More than 3 weeks since prior intracranial surgery and recovered	Eligibility	42
surgery	OAE:0000067	43-50
More than 4 weeks since prior radiotherapy and recovered	Eligibility	43
radiotherapy	OAE:0000235	30-42
More than 4 weeks since prior major surgery	Eligibility	44
surgery	OAE:0000067	36-43
More than 28 days since prior investigational compounds or drugs	Eligibility	45
No prior epothilones	Eligibility	46
No concurrent known diarrheagenic agents	Eligibility	47
No other concurrent anticancer agents, including investigational agents, biological agents, or chemotherapy	Eligibility	48
No other concurrent experimental therapies	Eligibility	49
Concurrent hormone therapy and/or trastuzumab (Herceptin®) allowed	Eligibility	50
hormone	CHEBI:24621	11-18
No concurrent Coumadin® or other agents containing warfarin	Eligibility	51
warfarin	CHEBI:10033	51-59
Low dose Coumadin® ( 1 mg) for prophylactic maintenance of indwelling lines or ports allowed	Eligibility	52
No concurrent radiotherapy for central metastases (e.g., vertebral or mediastinal metastases)	Eligibility	53
radiotherapy	OAE:0000235	14-26
central	HP:0030645	31-38
Concurrent radiotherapy for local peripheral metastases not being used as marker lesions allowed	Eligibility	54
radiotherapy	OAE:0000235	11-23
peripheral	HP:0030646	34-44
No concurrent prophylactic hematopoietic growth factors during course 1	Eligibility	55
growth	GO:0040007	41-47
No concurrent herbal or nontraditional medications	Eligibility	56
Outcome Measurement:	Results	0
Central Nervous System (CNS) Progression-free Survival(PFS)	Results	1
central nervous system	UBERON:0001017	0-22
The number of patients that are documented to have progression free survival at 3 months after treatment. Progression free is define as <25% increase in tumor area.	Results	2
increase	BAO:0001251	141-149
area	PATO:0001323	159-163
PFS will be measured from the date of entry into the trial to the date of documented progression of brain metastases or death.	Results	3
brain	UBERON:0000955	100-105
death	OAE:0000632	120-125
Time frame: 3 months after treatment	Results	4
time	PATO:0000165	0-4
Results 1:	Results	5
Arm/Group Title: Epothilone B: Group A	Results	6
epothilone b	CHEBI:31550	17-29
group	CHEBI:24433	4-9
group	CHEBI:24433	31-36
Arm/Group Description: Group A: Patients with progressive, radiographically measurable parenchymal brain metastases after whole brain radiation therapy (WBRT). Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.	Results	7
group	CHEBI:24433	4-9
group	CHEBI:24433	23-28
progressive	HP:0003676	46-57
brain	UBERON:0000955	99-104
brain	UBERON:0000955	128-133
body weight	CMO:0000012	338-349
Overall Number of Participants Analyzed: 45	Results	8
Measure Type: Number	Results	9
Unit of Measure: participants  12	Results	10
Results 2:	Results	11
Arm/Group Title: Epothilone B: Group B	Results	12
epothilone b	CHEBI:31550	17-29
group	CHEBI:24433	4-9
group	CHEBI:24433	31-36
Arm/Group Description: Group B: an exploratory cohort of patients, with either leptomeningeal metastases (LMD) or unirradiated, asymptomatic brain metastasis from breast cancer (BCBM).Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.	Results	13
group	CHEBI:24433	4-9
group	CHEBI:24433	23-28
brain	UBERON:0000955	141-146
breast cancer	DOID:1612	163-176
body weight	CMO:0000012	362-373
Overall Number of Participants Analyzed: 10	Results	14
Measure Type: Number	Results	15
Unit of Measure: participants  2	Results	16
Adverse Events 1:	Adverse Events	0
Total: 18/55 (32.73%)	Adverse Events	1
Anemia * 1/55 (1.82%)	Adverse Events	2
anemia	HP:0001903,DOID:2355	0-6
Neutropenia * 1/55 (1.82%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	0-11
Dehydration * 6/55 (10.91%)	Adverse Events	4
dehydration	HP:0001944	0-11
Diarrhea * 8/55 (14.55%)	Adverse Events	5
diarrhea	HP:0002014,DOID:13250	0-8
Hemorrhage, upper GI * 1/55 (1.82%)	Adverse Events	6
Ileus, GI (functional obstruction of bowel, i.e., neuroconstipation) * 1/55 (1.82%)	Adverse Events	7
ileus	HP:0002595,DOID:8440	0-5
functional	BAO:0000010	11-21
Nausea * 1/55 (1.82%)	Adverse Events	8
nausea	HP:0002018	0-6
Pain - Abdomen NOS (not otherwise specified) * 1/55 (1.82%)	Adverse Events	9
pain	HP:0012531	0-4
abdomen	UBERON:0000916	7-14
Ulcer, GI - Duodenum * 1/55 (1.82%)	Adverse Events	10
ulcer	OAE:0004372	0-5
duodenum	UBERON:0002114	12-20
Adverse Events 2:	Adverse Events	11
